10X Genomics

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

10X Genomics reports solid earnings, eyes growth through innovation

10X Genomics delivered solid earnings in Q4 2022, with revenue growth and strong product innovation driving market presence and customer engagement.
Despite challenges like operational constraints and margin expectations, the company focuses on financial sustainability and market adaptability for future growth.
Opportunities lie in new sample types exploration, product success with Xenium and Visium HD, and customer response to Chromium Flex, indicating potential for revenue growth and market expansion.
Balanced guidance discussions and a focus on key products position 10X Genomics for strategic growth in 2023, with a global market outlook and emphasis on innovation and customer satisfaction.

10x Genomics reports robust Q1 revenue growth, eyes operational efficiency

10x Genomics delivered strong revenue growth in Q1 2023, driven by spatial portfolio and Chromium consumables, with raised revenue guidance for the year.
The company faces challenges in China and margin pressures but sees opportunities in product enhancements, market expansion, and revenue diversification.
Overall, 10x Genomics is strategically positioned for growth, with a focus on operational efficiency, customer adoption, and revenue optimization.

10X Genomics reports robust Q2 growth amidst China challenges

10X Genomics saw strong revenue growth in Q2 2023, driven by single cell and spatial portfolios.
While facing challenges in China, opportunities lie in expanding applications and clinical adoption.
Operational improvements and product advancements position the company for future growth.
Focus on margin improvement and revenue diversification key for sustained success.

10x Genomics reports robust Q3 revenue growth and strategic realignment

10x Genomics showcased strong revenue growth driven by Xenium's success, with plans to enhance product offerings and rebalance resources for future growth.
Despite challenges in gross margin and flat Chromium revenue, the company remains optimistic about its outlook and growth potential in spatial placements.
Opportunities lie in leveraging Xenium's capabilities, driving consumable revenue through discounts, and focusing on the Chromium franchise for sustained growth.

10x Genomics reports strong Q4 earnings, eyes growth opportunities

10x Genomics anticipates revenue of $670-690 million for 2024.
Guidance philosophy balances upsides and downsides for growth.
Strategic focus on product portfolio and long-term gross margin profile.
Emphasis on investments for future growth and maintaining innovation.

10x Genomics reports Q1 revenue growth, tackles pricing challenges

10x Genomics saw strong revenue growth in spatial but faced challenges with new Chromium technology orders.
The company aims to drive adoption by reducing prices and expanding the total market for single-cell technology.
Customers are showing interest in multiple platforms, setting up genomics infrastructure with various use cases.
Despite obstacles, 10x Genomics remains optimistic about the potential of its technology platforms and market growth.

10X Genomics reports Q3 revenue decline, focuses on growth strategies

10X Genomics faced revenue decline in Q3 due to sales restructuring and cautious customer spending, with full-year revenue expected to decline by 3%. Despite challenges, the company is focused on driving growth through new product launches, evolving commercial structure, and expanding access to single cell analysis. Confidence in the company's path forward remains strong, with expectations for sequential improvements and a focus on long-term opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beam Therapeutics

Recursion Pharmaceuticals

Here's why our roundtable likes 10x Genomics, Beam Therapeutics, and Recursion Pharmaceuticals.

3 Cathie Wood Stocks That Could Deliver Monster Returns

Axsome Therapeutics

Doximity

Here's why three Fool.com contributors love 10x Genomics, Axsome Therapeutics, and Doximity.

My Favorite Biotech

Intuitive Surgical

NVIDIA

Analysts think the downturns for these stocks should only be temporary.

3 Unstoppable Stocks That Could Soar 58% to 97%, According to Wall Street

10x Genomics, Inc. (NASDAQ:TXG ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Cassie Corneau - Investor Relations and Strategic Finance Serge Saxonov - Chief Executive Officer & Co-founder Justin McAnear - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Dan Brennan - Cohen Mike Ryskin - Bank of America Julia Qin - JPMorgan Patrick Donnelly - Citi Matt Larew - William Blair Matt Sykes - Goldman Sachs Operator Hello and welcome to the 10x Genomics First Quarter 2022 Earnings Conference Call. My name is Katie and I'll be coordinating your call today.

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q1 2022 Results - Earnings Call Transcript

Q1 2022 revenue growth of 8% over prior year PLEASANTON, Calif. , May 4, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2022.

10x Genomics Reports First Quarter 2022 Financial Results

PLEASANTON, Calif. , April 26, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada.

10x Genomics to Present at the BofA Securities 2022 Healthcare Conference

This biotech's products are a must-have for scientists.

This Chart Is Why I'm Holding This Stock for the Next Decade

Fixed RNA Profiling Kit stabilizes human samples at collection; Nuclei Isolation Kit simplifies frozen sample analysis PLEASANTON, Calif. , April 14, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the commercial availability of two new products designed to improve sample preparation workflow and broaden the adoption of the company's leading Chromium platform for single cell analysis: Fixed RNA Profiling and Nuclei Isolation Kits.

10x Genomics Launches Two New Products to Unlock Wider Range of Samples for Single Cell Analysis on Chromium

PLEASANTON, Calif. , April 7, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 4, 2022.

10x Genomics to Report First Quarter Financial Results on May 4, 2022

Digital Turbine

Elastic N.V

MercadoLibre

SentinelOne

Teladoc

Twilio

The growth selloff continues to persist and with the Ukraine war raging, persistent inflation and rate hikes on the horizon, it makes sense that high multiple growth is largely out of favor.

Let's Go Dumpster Diving

SoFi Technologies

They're beaten down -- but perhaps for not too much longer.

3 Stocks Down 50% or More That Wall Street Thinks Could Nearly Double

PLEASANTON, Calif., March 1, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming Cowen 42nd Annual Health Care Conference.

10x Genomics to Present at the Cowen 42nd Annual Health Care Conference

PLEASANTON, Calif,, Feb. 22, 2022 /PRNewswire/ -- 10x Genomics , Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today unveiled new details about upcoming products and capabilities across its single cell, spatial, and in situ platforms at its second annual Xperience 2022 virtual event. Highlights included the Fixed RNA Profiling Kit, which improves sample preparation workflow and adds flexibility for Chromium single cell experiments; Visium CytAssist, to expand the number of tissue samples accessible to the spatial platform; and the first-ever look at the forthcoming Xenium Analyzer.

10x Genomics Showcases Robust Innovation Pipeline at Xperience 2022 Event

Investors were disappointed with the company's 2022 guidance.

Why 10x Genomics Stock Is Sinking Today

The stock fell by nearly 25% as markets reacted to the lab tools firm's 2022 revenue outlook.

10x Genomics Shares Dive on Weaker-Than-Expected Guidance

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q4 2021 Results - Earnings Call Transcript

10x Genomics (TXG) delivered earnings and revenue surprises of -166.67% and 2.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

10x Genomics (TXG) Reports Q4 Loss, Lags Revenue Estimates

PLEASANTON, Calif., Feb. 16, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided outlook for 2022.

10x Genomics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Outlook for 2022

ASML Hld

Ford Motor Company

Microsoft

Olaplex Holdings

Planet Labs

Rockwell Automation

Although there are plenty of risks abound due to monetary and geopolitical pressures, there are discounts to be had for stocks to love. The post 7 Stocks to Love for a Long, Long Time appeared first on InvestorPlace.

7 Stocks to Love for a Long, Long Time

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will 10x Genomics (TXG) Report Negative Earnings Next Week? What You Should Know

Affirm

BioNTech SE

Moderna

Rivian Automotive

A beaten-down stock is only a bargain if the sell-off was ultimately a mistake.

Is It Time to Buy January's 5 Worst-Performing Nasdaq Stocks?

Pieris Pharma

Sana Biotechnology

In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.

3 Biotechs That Will Soar Regardless of COVID-19

PLEASANTON, Calif., Jan. 26, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 after market close on Wednesday, February 16, 2022.

10x Genomics to Report Fourth Quarter and Full Year 2021 Financial Results on February 16, 2022

PLEASANTON, Calif., Jan. 21, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the expansion of its 10x Certified Service Provider (CSP) Network to include three leading clinical research organizations (CROs).

10x Genomics Adds Global Clinical Research Organizations to Expanded Certified Service Provider Network

PLEASANTON, Calif., Dec. 22, 2021 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today announced the company will be participating in the upcoming 40th Annual J.P.

News for 10X Genomics Stock (TXG)